title: Adrenal suppression from high-dose inhaled fluticasone propionate in children with asthma.
abstract: This cross-sectional study was designed to examine the prevalence of adrenocortical suppression in children with asthma treated with high-dose inhaled fluticasone propionate (FP). Children and adolescents (n=50) with asthma, treated with inhaled FP at a dose of > or = 1,000 mg a day for > or = 6 months, were enrolled. Early morning serum cortisol was performed. Subjects with a serum cortisol of < 400 nmol x L(-1) had a tetracosactrin stimulation test. Fifty subjects of mean age 13.1 yrs were treated with a mean dose of 924.7 microg x m(-2) x day(-1) FP for a mean duration of 2 yrs. Of the 50 subjects, 36 (72%) had serum cortisol levels of < 400 nmol x L(-1) and underwent tetracosactrin stimulation test. Of these, 6 (17%) demonstrated a less than two-fold increase in serum cortisol from baseline and peak cortisol level of < or = 550 nmol x L(-1) at 30 or 60 min poststimulation. There was a significant negative correlation between the dose of FP x m(-2) and stimulated peak cortisol level. Biochemical evidence of adrenocortical insufficiency was demonstrated in 12% of the subjects, indicating that high-dose fluticasone propionate use may be associated with dose-dependent adrenocortical suppression.
authors.affiliation: Dept of Respiratory and Sleep Medicine, Monash Medical Centre, Melbourne, Australia.
authors.forename: D
authors.initials: D
authors.lastname: Sim
authors.forename: A
authors.initials: A
authors.lastname: Griffiths
authors.forename: D
authors.initials: D
authors.lastname: Armstrong
authors.forename: C
authors.initials: C
authors.lastname: Clarke
authors.forename: C
authors.initials: C
authors.lastname: Rodda
authors.forename: N
authors.initials: N
authors.lastname: Freezer
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000311:Adrenal Glands / Q000187:drug effects*; D000730:Androstadienes / Q000009:adverse effects / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000097:blood / Q000188:drug therapy*; D002648:Child; D003366:Cosyntropin / Q000494:pharmacology; D003430:Cross-Sectional Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D000068298:Fluticasone; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D018709:Statistics, Nonparametric
chemical_list: D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D003366:Cosyntropin; D000068298:Fluticasone; D006854:Hydrocortisone